ACTION LADA - Prevalance characterisation & prevention of latent autoimmune diabetes in adults (lada) in europe (action lada) (LIFE QUALITY) (2002-12-01 - 2005-11-30) (»add to infobox)

Dean CURTIS, Bolo MAYWEG, Domenico ANDREANI, Gerhard BECKER, Christoph SCHNACK, Jussi HUTTUNEN, Inge Skov ANDERSEN, Yoram KARMON, Ann DUNCAN, Montserrat GRAU, Sean DONAGHY, Domitien DEBOUZIE, Phillip GOUGH

QUEEN MARY & WESTFIELD COLLEGE (UK550 - Greater London) (Great Britain), DEUTSCHE DIABETES FORSCHUNGSGESELLSCHAFT EV (DEA11 - Düsseldorf, Kreisfreie Stadt) (Germany), FONDAZIONE DIABETE ENDOCRINOLOGIA METABOLISMO (IT603 - Roma) (Italy), HEINRICH-HEINE-UNIVERSITAET DUESSELDORF (DEA11 - Düsseldorf, Kreisfreie Stadt) (Germany), INSTITUT FUER STOFFWECHSELFORSCHUNG (AT130 - Wien) (Austria), NATIONAL PUBLIC HEALTH INSTITUTE (FI110 - Uusimaa) (Finland), ODENSE UNIVERSITETSHOSPITAL (DK008 - Fyns amt) (Denmark), PEPTOR LTD (ME04 - Israel) (Israel), QUINTILES LTD (UK522 - Buckinghamshire) (Great Britain), RESEARCH INSTITUTE OF THE HOSPITAL DE SANTA CREU I SANT PAU (ES511 - Barcelona) (Spain), ROYAL GROUP OF HOSPITALS AND DENTAL HOSPITAL HEALTH AND SOCIAL SERVICES TRUST (UKB00 - Northern Ireland) (Great Britain), UNIVERSITE CLAUDE BERNARD LYON 1 (FR716 - Rhône) (France), UNIVERSITY OF WALES SWANSEA (UK924 - West Glamorgan) (Great Britain)

A substantial proportion of patients with non-insulin requiring diabetes progress to insulin therapy. Many cases, despite being adults, have immune and genetic features of autoimmune type 1 diabetes. Such adult autoimmune non-insulin requiring diabetic patients probably comprise the majority of cases of autoimmune diabetes in Europe and their condition is described as latent autoimmune diabetes of adults (LADA). This proposal aims: 1 ) to define the prevalence of LADA across Europe by testing non-insulin requiring diabetes patients for antibodies to glutamic acid decarboxylase; 2) to characterise LADA in terms of genetic, immune and metabolic features, and 3) to prevent or delay progression to insulin dependence in LADA using a immune modulation therapy with a heat shock protein altered peptide (Diapep 277). The double-blind randomised prevention trial will determine in a group of recent onset LADA patients whether therapy with Diapep277 can modify the natural history of the disease. Such therapy, if successful in reducing progression to insulin dependence, could be used to prevent autoimmune type 1 diabetes in children.

PERSONS (13/13)

RELATED NAVIGATION AREA(S) (1/1)